Equities analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post earnings of $0.21 per share for the current quarter, according to Zacks. Two analysts have made estimates for Meridian Bioscience’s earnings. The lowest EPS estimate is $0.20 and the highest is $0.21. Meridian Bioscience reported earnings of $0.19 per share during the same quarter last year, which would indicate a positive year over year growth rate of 10.5%. The firm is expected to report its next earnings report on Friday, November 12th.
According to Zacks, analysts expect that Meridian Bioscience will report full-year earnings of $1.64 per share for the current financial year, with EPS estimates ranging from $1.63 to $1.64. For the next year, analysts expect that the firm will post earnings of $1.08 per share, with EPS estimates ranging from $1.05 to $1.10. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.09). The company had revenue of $63.51 million during the quarter, compared to analyst estimates of $73.12 million. Meridian Bioscience had a net margin of 23.29% and a return on equity of 24.58%.
Several large investors have recently modified their holdings of VIVO. Colony Group LLC increased its stake in Meridian Bioscience by 1.1% during the second quarter. Colony Group LLC now owns 148,784 shares of the company’s stock valued at $3,300,000 after purchasing an additional 1,546 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in Meridian Bioscience by 107,323.1% in the second quarter. Metropolitan Life Insurance Co NY now owns 13,965 shares of the company’s stock worth $310,000 after purchasing an additional 13,952 shares during the period. Millennium Management LLC lifted its holdings in Meridian Bioscience by 19.0% in the second quarter. Millennium Management LLC now owns 401,287 shares of the company’s stock worth $8,901,000 after purchasing an additional 64,056 shares during the period. Man Group plc acquired a new stake in Meridian Bioscience in the second quarter worth about $231,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Meridian Bioscience by 2.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 35,908 shares of the company’s stock worth $796,000 after purchasing an additional 793 shares during the period. Institutional investors and hedge funds own 98.47% of the company’s stock.
Shares of VIVO stock traded down $0.39 during mid-day trading on Friday, hitting $19.27. The stock had a trading volume of 734 shares, compared to its average volume of 605,122. Meridian Bioscience has a fifty-two week low of $15.45 and a fifty-two week high of $30.65. The firm has a market cap of $835.43 million, a PE ratio of 12.14 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.31 and a quick ratio of 3.36. The company’s 50-day simple moving average is $19.78 and its 200-day simple moving average is $21.25.
About Meridian Bioscience
Meridian Bioscience, Inc engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products; and sale and distribution of diagnostics products domestically and abroad.
See Also: Dividend Kings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.